ALO-02

DRUG3 trials

Sponsors

Pfizer

Conditions

AnalgesiaChronic PainLow Back PainManagement of Moderate to Severe PainModerate-severe Pain

Phase 1

Pharmacokinetics Study of ALO-02 and OxyContin

CompletedNCT01557257

PfizerManagement of Moderate to Severe Pain

Start: 2012-03-31End: 2012-05-31Updated: 2012-06-28

Phase 3

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

CompletedNCT01571362

PfizerChronic Pain, Low Back Pain, Analgesia

Start: 2012-06-30End: 2013-06-30Updated: 2017-04-04

Phase 4

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

TerminatedNCT02680847

PfizerModerate-severe Pain

Start: 2016-01-21End: 2018-01-24Updated: 2018-09-25

Related Papers

Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone

Journal of Opioid Management2019-09-013 citations

Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials

Current Medical Research and Opinion2019-08-28

Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.

2017-10-174 citations